Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 21-40 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 21 | GalaxEye mediummedium | Opp 7 Risk 4 | Thesis: GalaxEye has the clearest opportunity evidence in the screen because it moved from pre-launch to an actual in-orbit milestone for Mission Drishti, described as the first OptoSAR satellite, and also has evidence of a commercialization path via an NSIL data-resale arrangement. For a 1 year+ horizon, a successful first satellite launch can support follow-on constellation buildout, data sales, and fundraising progression if commissioning and execution continue. Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available. Evidence
Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain |
| 22 | Loft Orbital mediummedium | Opp 7 Risk 3 | Thesis: Loft Orbital has the strongest opportunity case in this screen because multiple dated within the recent evidence window articles describe a multi-year CNES contract worth up to tens of millions of euros for a next-generation Earth observation constellation, with the first satellite scheduled for Q4 2026 or by year-end 2026. Additional 2026 context says Loft is expanding from hosted payloads into full-service 'constellations as a service,' which supports a durable 1 year+ strategic scaling thesis. Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'. Evidence
Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing. |
| 23 | Momentus mediummedium | Opp 7 Risk 5 | Thesis: Momentus has credible 1 year+ opportunity from recent execution milestones and commercial/government traction: Vigoride 7 launched in late March 2026, and in June 2026 the company announced a new commercial contract for Vigoride-9 in-orbit services. This supports product progression from demonstration toward revenue-bearing missions. Why now: Why-now is supported by recent mission and contract evidence within the recent evidence window: on March 30, 2026 Momentus announced the successful launch of Vigoride 7 and called it its most advanced on-orbit demonstration campaign to date; on June 17, 2026 it announced a new commercial contract with LASP to host and operate the OWLS mission on Vigoride-9, expanding its commercial revenue portfolio. Evidence
Caveats: The SHIELD contract-vehicle selection is dated December 10, 2025 and outside the 90-day recent evidence window, so it is useful background but not a recency catalyst here. Some weak context rows repeat the same article-level claims and are not independent confirmation. |
| 24 | Open Cosmos mediummedium | Opp 7 Risk 3 | Thesis: Open Cosmos has the clearest visible operating-progress evidence in the screen. A June 17, 2026 article says it launched the first two satellites of its new Ka-band LEO telecom constellation and had secured a license from Liechtenstein a week earlier to use high-priority radio bands, indicating actual network rollout and regulatory progress toward sovereign and secure communications offerings for governments and enterprises. Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries. Evidence
Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation. |
| 25 | Rocket Lab USA, Inc. highstrong | Opp 7 Risk 4 | Thesis: Rocket Lab has credible long-horizon opportunity from expanding beyond launch into higher-value national security satellite production and operations, while also showing continued commercial launch execution. Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective. Evidence
Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof. |
| 26 | Sateliot mediummedium | Opp 7 Risk 5 | Thesis: Sateliot has a solid 1 year+ opportunity setup because company-linked facts say it launched a €100 million Series C round to deploy 16 satellites for 5G IoT and direct-to-device connectivity, while later article context adds that it signed its first commercial contract for a dedicated LEO launch for two Tritó satellites in 2027. The combination of financing and launch planning supports constellation build-out potential. Why now: The sequence matters: the company launched the Series C on April 8, 2026/April 13, 2026, then later reporting on May 21, 2026 noted a first commercial launch contract, and June 24, 2026 reporting still described the round as seeking capital and a lead investor. That mix creates both opportunity and financing risk over a 1 year+ horizon. Evidence
Caveats: The reviewed sources does not provide a direct positive event row for the first commercial contract; that support is supporting article context and weaker than a structured company event row. Later dated coverage indicates financing is still being sought, which partially offsets the opportunity thesis. Undated context items exist in the reviewed sources but are not used for recency-sensitive judgments. |
| 27 | SatSure mediummedium | Opp 7 Risk 4 | Thesis: SatSure has the strongest non-Boeing opportunity setup in this screen because multiple recent article summaries indicate it secured a 246 million rupee ($2.57 million) grant from India's space regulator to develop AI-powered Earth observation models, and a later June 2026 article says Safran Electronics & Defense and SatSure signed an MoU to collaborate on GEOINT solutions for the Indian market. Together these suggest both public-sector support and ecosystem partnership momentum relevant over a 1 year+ horizon Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context Evidence
Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones. |
| 28 | Starfish Space mediumstrong | Opp 7 Risk 3 | Thesis: Starfish Space has the strongest positive evidence in the screen: recent Series B funding of more than $100 million and company-linked evidence of existing work with Space Force, NASA, and SES support a multi-year scaling thesis in on-orbit servicing. Why now: The timing is favorable for a 1 year+ horizon because recent financing on April 7, 2026 was explicitly tied to executing first servicing missions and boosting production, following prior government contract momentum Evidence
Caveats: The strongest support is external web-search evidence, though it is company-linked and dated. Some contract details in weaker article context vary and should not be over-aggregated across repeated articles. |
| 29 | TakeMe2Space mediummedium | Opp 7 Risk 3 | Thesis: TakeMe2Space has recent funding support from IN-SPACe under the Technology Adoption Fund, with the article stating selected startups will each receive up to ₹25 crore, which supports a durable financing-and-development opportunity over a 1 year+ horizon. Why now: The IN-SPACe funding article is dated June 12, 2026, very recent within the recent evidence window, and describes first investment into selected Indian spacetech startups including TakeMe2Space, which could shape the next year of development. Source date: June 12, 2026 Evidence
Caveats: Reviewed evidence notes prior broader membership support, but only one in-window article context is retained here. Evidence is supporting article context only despite stronger historical support counts. |
| 30 | Turion Space mediummedium | Opp 7 Risk 5 | Thesis: Turion Space has credible long-horizon opportunity because the reviewed sources show a sizable Series B closed on April 15, 2026 to accelerate deployment of its space domain awareness satellite fleet, alongside evidence that it has already launched spacecraft and is expanding a maneuverable satellite fleet for in-orbit observation missions. Why now: The key timing driver is the dated financing round on April 15, 2026, which the reviewed sources say positions the company to scale beyond single-mission spacecraft toward a persistent SDA constellation, a development relevant over a 1 year+ horizon. Evidence
Caveats: The reviewed sources have no direct positive or negative dated events; the case relies on supporting article context rather than stronger internal company-specific events. The company website context on May 23, 2026 is weaker than independent company-specific event evidence and should not be overweighted. Citation |
| 31 | Astrobase Space Technologies mediummedium | Opp 6 Risk 4 | Thesis: Astrobase has visible funding support tied to a specific propulsion-development goal. A June 12, 2026 article says IN-SPACe selected it under the Technology Adoption Fund and that each project can receive up to ₹25 crore; the same summary says Astrobase aims to develop a high-thrust closed-cycle liquid rocket engine. For a 1 year+ horizon, non-dilutive or quasi-public funding for propulsion development is a meaningful opportunity signal. Why now: The funding article is recent, with published June 12, 2026, and specifically notes this as IN-SPACe's first investment in Indian startups under the TAF scheme. That timing matters for a 1 year+ horizon because it may enable development progress over coming quarters. Evidence
Caveats: Visible evidence is only one external article summary despite the membership rationale referencing multiple structured support articles. No technical test results or customer contracts are provided in the exposed evidence. |
| 32 | Blue Origin mediummedium | Opp 6 Risk 7 | Thesis: Blue Origin has meaningful long-horizon upside from multiple recent demand signals: a Space Force national security launch task order, a planned return-to-service New Glenn launch for 48 Amazon Leo satellites, and a NASA moon-base award tied to a fall 2026 target window. Why now: The setup is active and recent: on May 30, 2026 SpaceNews reported Blue Origin received an NSSL task order hours before a New Glenn explosion, while on May 27, 2026 GeekWire reported New Glenn was preparing to return to service for an Amazon Leo mission after its first launch failure; on May 26, 2026 Investing.com summarized a NASA moon-base contract with launch no earlier than fall 2026 Evidence
Caveats: Positive evidence is mostly supporting article context rather than direct events. One external article is undated and is not relied on for recency proof. Government support after the anomaly partially offsets, but does not erase, execution risk. |
| 33 | ElevationSpace mediummedium | Opp 6 Risk 2 | Thesis: ElevationSpace has one of the better opportunity setups in this screen because the reviewed sources includes a recent dated article saying it raised $40 million in Series B funding, bringing total raised to $63.5 million, for a business developing space-to-Earth transportation and a space environment utilization and recovery platform. A large recent financing can support product development and scaling over a 1 year+ horizon. Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon. Evidence
Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration. |
| 34 | General Atomics mediummedium | Opp 6 Risk 2 | Thesis: General Atomics has the clearest opportunity signal in the screen because an article dated April 8, 2026 says Space Systems Command awarded 14 companies more than $1.8 billion in Andromeda contracts for the Geosynchronous Reconnaissance & Surveillance Constellation, and General Atomics is named among the companies. For a 1 year+ horizon, inclusion in a large U.S. defense-space procurement could support durable program participation if it converts into funded work streams, though the reviewed sources only provides supporting article context rather than a direct company event row., April 8, 2026 Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026 Evidence
Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation. |
| 35 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: GITAI has the strongest opportunity setup in this screen because a dated June 16, 2026 company announcement says it completed the flight model of its S3 robotic satellite mission for an on-orbit servicing technology demonstration and framed the platform as supporting future defense-focused LEO constellation services, indicating tangible program maturation rather than just category membership. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 36 | Intuitive Machines, Inc. mediummedium | Opp 6 Risk 5 | Thesis: Intuitive Machines has moderate long-horizon opportunity because recent Space Force selection expands its relevance beyond lunar services into space surveillance capabilities, potentially broadening its addressable defense business. Why now: The timing case comes from May 12, 2026 reporting that Intuitive Machines was selected for the Space Force Andromeda IDIQ to develop space surveillance capabilities through 2030 and beyond, described as the company's first major selection following the Lanteris Space acquisition. Evidence
Caveats: The reviewed sources provide supporting article context but no direct structured fact with quantified contract value specific to Intuitive Machines. No direct adverse evidence is available; risk is based on competitive award structure and evidence limitations. Long-horizon upside depends on conversion from selection status into meaningful programs. |
| 37 | Kepler mediummedium | Opp 6 Risk 3 | Thesis: Kepler shows a meaningful operational milestone: the company said it successfully launched the first tranche of optical relay satellites and that a 10-satellite ring marks the beginning of its operational optical data relay network. For a 1 year+ horizon, first-network deployment can support follow-on service activation and adoption. Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement. Evidence
Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation. |
| 38 | L3Harris Technologies mediummedium | Opp 6 Risk 3 | Thesis: L3Harris has a moderate opportunity case from current participation in the Space Force’s Andromeda space domain awareness effort, which could support multi-year defense-space positioning. Recent article context published April 8, 2026 lists L3Harris among the companies awarded Andromeda contracts for RG-XX satellites. Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context. Evidence
Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'. |
| 39 | Lockheed Martin mediummedium | Opp 6 Risk 2 | Thesis: Recent supporting article context indicates Lockheed Martin won a Space Force contract worth up to $105 million to modernize the GPS ground control network and support GPS IIIF operations, which supports a durable government-space revenue opportunity over a 1 year+ horizon. Why now: The relevant contract article is dated April 16, 2026, inside the 90-day recent evidence window, and describes current modernization work tied to GPS IIIF support, which can matter over a multi-quarter horizon. Source date: April 16, 2026 Evidence
Caveats: Evidence is supporting article context only; no direct positive event row is available. Same article appears in multiple weak-context rows and does not count as independent confirmation. |
| 40 | Logos Space Services mediummedium | Opp 6 Risk 4 | Thesis: Among this screen, Logos has the clearest in-recent evidence window strategic progress: it recently secured FCC approval for a very large broadband constellation of up to 4,178 satellites, which is a meaningful regulatory milestone for a long-horizon satellite communications buildout. Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon. Evidence
Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |